Skip to main content
SpringerLink
Log in
Book cover

Neurological Adverse Reactions to Anticancer Drugs pp 25–43Cite as

Mechanisms of Neurotoxicity and Experimental Models

  • Conference paper

  • 30 Accesses

Part of the book series: ESO Monographs ((ESO MONOGRAPHS))

Abstract

The mechanisms of action underlying the neurotoxicity caused by chemotherapeutic drugs can be related to the mechanism by which the drug exerts its anticancer activity, but may also be totally different. In order to be able to study these mechanisms, the development and use of in-vitro and in-vivo test models are indispensable. In addition, the models may provide a preclinical tool to test possible methods for prevention and treatment of drug-related neurotoxicity. In the first place, it can be stated that the number of available models is small, whereas most of the existing models can be strictly applied only to a specific class of anticancer drugs. Another aspect, of equal importance, is the often underestimated influence of pharmacological parameters, such as the route of administration, the kinetics of the drug and drug interactions.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Rosenberg B: Fundamental studies with cisplatinum. Cancer 1985 (55):2303–2316

    Article  PubMed  CAS  Google Scholar 

  2. Filipski J, Kohn KW, Bonner WM: The nature of inactivating lesions produced by platinum (II) complexes in phase lambda DNA. Chem Biol Interactions 1980 (32):321–330

    Article  CAS  Google Scholar 

  3. Srivastava RC, Froehlich J, Eichhorn GL: The effect of platinum binding on the structure of DNS and its function in RNA synthesis. Biochimie 1978 (60):879–891

    Article  CAS  Google Scholar 

  4. Stone PS, Kelman AD, Sinex FM: Specific binding of antitumour durg cis-Pt (NH3) 2C12 to DNA rich in guanine and cytosine. Nature 1974 (251):736–737

    Article  PubMed  CAS  Google Scholar 

  5. Roberts JJ, Fravel HNA: The interaction of antitumour platinum compounds with cellular DNA in cultured cells and animal tissues: relationship to DNA cellular repair processes. Biochimie 1978 (60):869–877

    Article  CAS  Google Scholar 

  6. Roelofs Rl, Hrushesky W, Rogin J, Rosenberg L: Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 1984 (34):934–938

    PubMed  CAS  Google Scholar 

  7. Thompson SW, Davis LE, Kornfeld M, Hilgers RD, Standefer KJC: Cisplatin neuropathy: clinical, electrophysiological, morphologic and toxicologic studies. Cancer 1984 (54):1269–1275

    Article  PubMed  CAS  Google Scholar 

  8. Thomas PK, Olsson Y: Connective tissue components of peripheral nerve. In: Dyck et al (eds) Peripheral Neuropathy. Saunders, Philadelphia 1984 pp 111–120

    Google Scholar 

  9. Terheggen PMAB, Gerritsen van der Hoop R, Floot BGJ, Gispen WH: Cellular distribution of cisdiamminedichloroplatinum (II)-DNA binding in rat dorsal root spinal ganglia: effect of the neuroprotecting peptide Org 2766. Toxicol Appl Pharmacol 1989 (99):334–343

    Article  PubMed  CAS  Google Scholar 

  10. Muller LJ, Gerritsen van der Hoop R, Moorer-van Delft CM, Gispen WH, Roubos EW: Morphological and electrophysiological study of the effects of cisplatin in Org 2766 on rat spinal ganglion neurons. Cancer Res (in press)

    Google Scholar 

  11. Tomiwa K, Nolan C, Cavanagh JB: The effects of cisplatin on rat spinal ganglia: a study by light and electron microscopy and by morphometry. Acta Neuropathol 1986 (69):295–308

    Article  PubMed  CAS  Google Scholar 

  12. Stewart D, Montpetit V, Mikhael N et al: Cisplatin neuropathy. Proc AACR 1989 (30):246

    Google Scholar 

  13. Stewart DJ, Wallace S, Feun L et al: A phase I study of intracarotid artery infusion of cisdiammindichloroplatinum (II) in patients with recurrent malignant intracerebral tumors. Cancer Res 1982 (42):2059–2062

    PubMed  CAS  Google Scholar 

  14. Neuwelt EA, Barnett PA, Glassberg M, Frenkel EP: Pharmacology and neurotoxicity of cisdiamminedichloroplatinum, bleomycin, 5-fluorouracil and cyclophosphamide administration following osmotic blood-brain barrier modification. Cancer Res 1983 (43):5278–5285

    PubMed  CAS  Google Scholar 

  15. Gormley PE, Gangji D, Wood JH, Poplack DG: Pharmacokinetic study of CNS penetration of cisdiaminedichloro platinum. Cancer Chemother Pharmacol 1981 (5):257–260

    Article  PubMed  CAS  Google Scholar 

  16. De Koning P, Neijt JP, Jennekens FGI, Gispen WH: Evaluation of Cis-Diamminedichloroplatinum (II) (cisplatin) neurotoxicity in rats. Toxicol Appl Pharmacol 1987 (89):81–87

    Article  PubMed  Google Scholar 

  17. Gastaut JL, Pellisier JF: Neuropathie au cisplatine: etude clinique, électrophysiologique et morphologique. Rev Neurol 1985 (141):614–626

    PubMed  CAS  Google Scholar 

  18. Rebert CS, Pryor GT, Frick MS: Effects of vincristine, maytansine, and cis-platinum on behavioral and electrophysiological indices of neurotoxicity in the rat. J Appl Toxicol 1984 (4):330–338

    Article  PubMed  CAS  Google Scholar 

  19. Gerritsen van der Hoop R, Neijt JP, Kennekens FGI, Gispen WH: Protection from cisplating induced neuropathy in rats by the ACTH (4-9) analog Org 2766. In: Pleasure D, Fiori M, Scarlato G, Scarpini E (eds) Proc. Peripheral Nerve Development and Regeneration. Livinia, Springer Verlag 1989 (19) pp 145–148

    Google Scholar 

  20. Gerritsen van der Hoop R: Prevention and treatment of cisplatin-induced neurotoxicity by Org 2766, and ACTH (4-9) analog. Thesis, Utrecht, 1989 pp 82–92

    Google Scholar 

  21. Elderson A, Gerritsen van der Hoop R, Haanstra W, Neijt JP, Gispen WH, Jennekens FGI: Vibration perception and thermoperception as quantitative measurements in the monitoring of cisplatin induced neuropathy. J Neurol Sci 1989 (93):167–174

    Article  PubMed  CAS  Google Scholar 

  22. De Koning P, Neijt JP, Jennekens FGI, Gispen WH: Org 2766 protects from cisplatin induced neurotoxicity in rats. Exp Neurol 1988 (97):746–750

    Article  Google Scholar 

  23. Gerritsen van der Hoop R, De Koning P, Boven E, Neijt JP, Jennekens FGI, Gispen WH: Efficacy of the neuropeptide Org 2766 in the prevention and treatment of cisplatin-induced neurotoxicity in rats. Eur J Cancer Clin Oncol 1988 (24):637–642

    Article  Google Scholar 

  24. Gerritsen van der Hoop R, Vecht ChJ, Van der Burg MEL, Elderson A, Boogerd N, Hermans JJ, Vries JC, van Houwellin G, Jennekens FGI, Gispen WH, Neijt JP: Org 2766, an ACTH (4-9) analog, prevents cisplatin induced neuropathy in ovarian cancer patients. N Engl J Med 1990 (322):89–94

    Article  Google Scholar 

  25. Mollman, Glover J, Hogan M, Furman RE: Cis Platin Neuropathy. Risk factors, prognosis and protection by WR-2721. Cancer 1988 (61 ):2192–2195

    Article  PubMed  CAS  Google Scholar 

  26. Hoeve LJ, Mertens zur Borg IRAM, Rodenburg M, Brocaar MP, Groen BGS: Correlation between cisplatinum dosage and toxicity in a guinea pig model. Arch Otorhinolaryngol 1988 (245):98–102

    Article  PubMed  CAS  Google Scholar 

  27. Baranak CC, Wetmore RF, Packer RJ: Cis-platinum ototoxicity after radiation treatment: an animal model. J Neurooncol 1988 (6):261–267

    Article  PubMed  CAS  Google Scholar 

  28. Granowetter L, Rosenstock JG, Packer RJ: Enhanced cis-platinum neurotoxicity in pediatric patients with brain tumors. J Neurooncol 1983 (1):293–297

    Article  PubMed  CAS  Google Scholar 

  29. Wagstaff AJ, Ward A, Benfield P, Heel RC: Carboplatin: a preliminary review of its pharmacodynamics and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs 1989 (37):162–190

    Article  PubMed  CAS  Google Scholar 

  30. Boven E, Van Der Vijgh WSF, Nauta MM, Schluper HMM, Pinedo HM: Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts. Cancer Res 1985 (45):86–90

    PubMed  CAS  Google Scholar 

  31. Bhattacharyya B, Wolff J: Membrane-bound tubulin in brain and thyroid tissue. J Biol Chem 1975 (250):7639–7646

    PubMed  CAS  Google Scholar 

  32. Hemminski K: Effects of colchicine and cytochalasin B on labelling and enzyme activities of brain plasma membranes. Int J Neurosci 1973 (6):159–163

    Article  Google Scholar 

  33. Hindelang-Gertner C, Stoeckel ME, Porte A, Stertinsky F: Colchicine effects on neurosecretory neurons and other hypothalamic and hypophysial cell, with special reference to changes in the cytoplasmic membranes. Cell Tiss Res 1976 (170):17–41

    Article  CAS  Google Scholar 

  34. Geraerts WPM, Ter Maat A, Vreughdehil E: The peptidergic neuroendocrine control of egg-laying behavior in Aphysia and Lymnea. In: Laufer H, Downer R (eds) Inter Vertebrate Endrocrinology. AR Liss Inc.,New York 1988 (Vol. 2) pp 141–231

    Google Scholar 

  35. Green LS, Donoso JA, Heller-Bettinger IE, Samson FE: Axonal transport disturbances in vincristineinduced peripheral neuropathy. Ann Neurol 1977 (1):255–262

    Article  PubMed  CAS  Google Scholar 

  36. Goldschmidt RB, Steward O: Comparison of the neurotoxic effects of colchicine, the vinca alkaloids and other microtubule poisons. Brain Res 1989 (486):133–140

    Article  PubMed  CAS  Google Scholar 

  37. Dustin P: Microtubules. Springer-Verlag London, Heidelberg 1978

    Google Scholar 

  38. Schlaepfer WW: Vincristine-induced axonal alterations in rat peripheral nerve. J Neuropathol Experim Neurol 1971 (30):488–505

    Article  CAS  Google Scholar 

  39. Donoso JA, Green LS, Heller-Bettinger IE, Samson FE: Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on axonal fibrillar organelles in vitro. Cancer Res 1977 (37):1401–1407

    PubMed  CAS  Google Scholar 

  40. Muller LJ, Moorer van Delft CM, Roubos EW: Snail neurons as a possible model for testing neurotoxic side effects of antitumour agents: Paracrital formation by vinca alkaloids. Cancer Res 1988 (48):7184–7188

    PubMed  CAS  Google Scholar 

  41. Menesini Chen MG, Chen JS, Calissano P, Levi Montalcini R: Nerve growth factor prevents vinblastine destructive effects on sympathetic ganglia in newborn mice. Proc Natl Acad Sci 1977 (74):5559–5563

    Article  Google Scholar 

  42. Owellen RJ, Owens AH, Donigan DW: The binding of vincristine, vinblastine and colchicine to tubulin. Biochem Biophys Res Commun 1972 (47):685–691

    Article  PubMed  CAS  Google Scholar 

  43. Takasugi BJ, Jones SE, Robertone AB: Phase II trial of vinzolidine, an oral vinca alkaloid, in Hodgkin‘s disease and non-Hodgkin’s lymphoma. Cancer Treat Rep 1984 (68):1399–1401

    PubMed  CAS  Google Scholar 

  44. Binet S, Fellows A, Lataste H, Krikorian A, Couzimier JP, Meininger V: In situ analysis of the action of navelbine on various types of microtubules using immunofluorescence. Semin Oncol 1989 (16):5–8

    PubMed  CAS  Google Scholar 

  45. Gerzun K, Ochs S, Todd GG: Polarity of vincristine, vindasine and vinblastine in relation to neurological effects. Proc Am Assoc Cancer Res 1979 (20):46

    Google Scholar 

  46. Nelson RL, Dyke RW, Root MA: Comparative pharmacokinetics of vindesine, vincristine and vinblastine in patients with cancer. Cancer Treat Rev 1980 (7):17–24

    Article  PubMed  Google Scholar 

  47. Noble RL, Gout PW, Wijcik LL, Hebden HF, Beer CT: The distribution of 3Hvinblastine in tumor and host tissues of Nb rats bearing a transplantable lymphoma which is highly sensitive to the alkaloid. Cancer Res 1977 (37):1455–1460

    PubMed  CAS  Google Scholar 

  48. Jackson DV, Sethi VS, Spurr CL, McWorther JM: Pharmacokinetics of vincristine in the cerebrospinal fluid of humans. Cancer Res 1981 (41):1466–1468

    PubMed  Google Scholar 

  49. Jackson DV, Castle MC, Poplack DG: Pharmacokinetics of vincristine in the cerebrospinal fluid of sub-human primates. Cancer Res 1980 (40):722–724

    PubMed  CAS  Google Scholar 

  50. Gaidys WG, Dickerman JD, Walters CL, Young PC: Intrathecal vincristine: Report of a fatal case despite CNS washout. Cancer 1983 (52):799–801

    Article  PubMed  CAS  Google Scholar 

  51. Letourneau PC, Ressler AH: Inhibition of neurite initiation and growth by taxol. J Cell Biol 1984 (98):1355–1362

    Article  PubMed  CAS  Google Scholar 

  52. Masurovsky EB, Peterson ER, Crain SM, Horfowitz SB: Microtubule arrays in taxol treated mouse dorsal root ganglia-spinal cord cultures. Brain Res 1981 (217):392–398

    Article  PubMed  CAS  Google Scholar 

  53. Parnass J, Horowitz SB: Taxol binds to polymerized in vitro. J Cell Biol 1981 (91):479–487

    Article  Google Scholar 

  54. Slotwiner P, Song SK, Anderson PJ: Spheromembrenous degeneration of muscle induced by vincristine. Arch Neurol 1966 (15):172–176

    PubMed  CAS  Google Scholar 

  55. Graff GLA, Geuning C, Hildebrand J: Action de sulfate de vincristine sur le gastrocnemien du rat II. Effects indépendants de Palcaloide et de la dénervation motrice sur le métabolisme des phosphates inorganismes, organiques acidosoluble et des phosphalipides. Cr Soc Biol 1966 (162):588–593

    Google Scholar 

  56. Gottschalk PG, Dyck PJ, Kiely JM: Vinca alkaloid neuropathy: nerve biopsy studies in rats and in men. Neurology 1968 (18):875–882

    PubMed  CAS  Google Scholar 

  57. Norido F, Finesso C, Fiorito P, Marino P et al: General toxicity and peripheral nerve alterations induced by chronic vincristine treatment in rabbit. Toxicology Appl Pharmacol 1988 (93):433–441

    Article  CAS  Google Scholar 

  58. Muller U, Moorer-Van Delft CM, Roubos EW: Snail neuron as a possible model for listing neurotoxic side effects of antitumor agents. Paracristal formation by vinca alkaloids. Cancer Res 1988 (48):7184–7188

    PubMed  CAS  Google Scholar 

  59. Favaro G, Di Gregorio F, Panazzo C, Fiori MG: Ganglioside treatment of vincristine-induced neuropathy. An electrophysiologic study. Toxicology 1988 (49):325–329

    Article  PubMed  CAS  Google Scholar 

  60. Hellmann K, Hutchinson GE, Henry K: Reduction of vincristine toxicity by cronasial. Cancer Chemother Pharmacol 1987 (20):21–25

    Article  PubMed  CAS  Google Scholar 

  61. Jackson DV Jr, Rosenbaum DL, Carlisle LH, Long TR, Wells HG, Spurr CL: Glutamic acid modifications of vincristine toxicity. Cancer Biochem Biophys 1984 (7):245–252

    PubMed  CAS  Google Scholar 

  62. Jackson DV, Wells HB, Atkins JN, Zekan PJ, White DR, Richards F, Gruz JM, Muss HM: Amelioration of vincristine neurotoxicity by glutamic acid. Am J Med 1988 (84):1016–1022

    Article  PubMed  CAS  Google Scholar 

  63. Jolivet J, Cowan KH, Curt GA, Clendenin NJ, Chabner BA: The pharmacology and clinical use of methotrexate. N Engl J Med 1983 (3):1094–1104

    Article  Google Scholar 

  64. Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Koizumi S, Drake JC, Jolivet J: Polyglutamation of methotrexate. J Clin Invest 1985 (76):907–912

    Article  PubMed  CAS  Google Scholar 

  65. Pinedo HM, Chabner BA: Role of drug concentration, duration of exposure and endogenous metabolites in determining methotrexate cytotoxicity. Cancer Treat Rep 1977 (61):709–715

    PubMed  CAS  Google Scholar 

  66. Gangji D, Ducore J, Poplack D, Kohn K, Glaubiger D: Concentration and time dependance of methotrexate cytotoxicity in mouse L1210 leukemia cells and human Burkitt’s lymphoma cells. Clin Res 1980 (28):525

    Google Scholar 

  67. Goldie JH, Price LA, Harrap KR: Methotrexate toxicity: correlation with duration of administration, plasma level doses and excretion pattern. Eur J Cancer 1972 (8):409–414

    Article  PubMed  CAS  Google Scholar 

  68. Ackland SD, Schilsky RL: High-dose methotrexate: a critical reappraisal. J Clin Oncol 1987 (5):2017–2031

    PubMed  CAS  Google Scholar 

  69. Bleyer WA: Neurological sequelae of methotrexate and ionising. A new classification. Cancer Treat Rep 1981 (65):89–98

    PubMed  Google Scholar 

  70. Price RA, Jamieson PA: The central nervous system in childhood leukemia. II subacute leukoencephalopathy. Cancer 1975 (35):306–318

    Article  PubMed  CAS  Google Scholar 

  71. Rubinstein LJ, Herman MM, Long TF, Wilbur JR: Disseminated necrotizing leukoencephalopathy: a complication of treated central nervous system leukemia and lymphoma. Cancer 1975 (35):291–305

    Article  PubMed  CAS  Google Scholar 

  72. Gangji D, Reaman GH, Cohen SR, Bleyer WA, Poplack DG: Leukoencephalopathy and elevated levels of myelin basic protein in the cerebrospinal fluid of patients with acute lymphoblastic leukemia. N Engl J Med 1980 (303): 19–21

    Article  PubMed  CAS  Google Scholar 

  73. Price RA: Therapy related central nervous system diseases in children with acute lymphocytic leukemia. In: Mastrangelo R, Poplack DG, Riccardi R (eds) Central Nervous system Leukemia Prevention and Treatment. Martinus Nijhof, Boston 1983 pp 71–83

    Chapter  Google Scholar 

  74. Allen JC, Rosen G, Metha BM: Leucoencephalopathy following high-dose IV methotrexate with leucovorin rescue. Cancer Treat Rep 1980 (64):1261 -1273

    PubMed  CAS  Google Scholar 

  75. Neijstrom E, Gabriel DA: High-dose methotrexateinduced neurotoxicity associated with elevation of CSF myelin basic protein. J Clin Oncol 1985 (3):593–594

    PubMed  CAS  Google Scholar 

  76. Yap H, Blumenshein GR, Yap BS: High-dose methotrexate for advanced breast cancer. Cancer Treat Rep 1979 (63):757–761

    PubMed  CAS  Google Scholar 

  77. Wernick R, Smith: Central nervous system toxicity associated with weekly low-dose methotrexate treatment. Arthritis Rheum 1989 (32):770–775

    Article  PubMed  CAS  Google Scholar 

  78. Geieser CF, Bishop Y, Jaffe N, Furman L, Traggis D, Frei E: Adverse effects of intrathecal methotrexate in children with acute leukemia in remission. Blood 1975 (45):189–195

    Google Scholar 

  79. Nathan PW, Sears TA: Action of methylhydroxybenzoate on nervous conduction. Nature 1961 (192):668–669

    Article  PubMed  CAS  Google Scholar 

  80. Hahn AF, Feasby TE, Gilbert JJ: Paraparesis following intrathecal chemotherapy. Neurology 1983 (33):1032–1038

    PubMed  CAS  Google Scholar 

  81. Dutera MJ, Bleyer WA, Pomeroy TC, Leventhal C, Leventhal BG: Irradiation, methotrexate toxicity and the treatment of meningeal leukemia. Lancet 1971 (1):703–772

    Google Scholar 

  82. Bleyer WA, Drake JC, Chabner BA: Neurotoxicity and elevated cerebrospinal fluid methotrexate concentration in meningeal leukemia. N Engl J Med 1973 (289):770–773

    Article  PubMed  CAS  Google Scholar 

  83. Bleyer WA, Poplack DG, Simon RM: Concentration x time methotrexate via a subcutaneous reservoir: a less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood 1978 (51):835–842

    PubMed  CAS  Google Scholar 

  84. Bleyer WA, Savitch JL, Holcenberg JS: An improved regimen for intrathecal chemotherapy. Clin Pharmacol Exp Ther 1976 (19):103–104

    Google Scholar 

  85. Dufner PK, Cohen ME, Brecher ML, Berer D, Parthasarathy KL, Bakshi S, Ettinger LF, Freeman A: CT abnormalities and altered methotrexate clearances in children with CNS leukemia. Neurology 1984 (34):229–233

    Google Scholar 

  86. Morse M, Savitch J, Balis F, Miser J, Feusner J, Reaman G, Poplack DG, Bleyer AW: Altered central nervous system pharmacology of methotrexate in childhood leukemia: Another sign of meningeal relapse. J Clin Oncol 1985 (3):19–24

    PubMed  CAS  Google Scholar 

  87. Grossman SA, Chen DCP, Thompson G: Cerebrospinal fluid abnormalities in patients with the neoplastic meningitis. An evaluation using “indium-DTPA ventriculography”. Am J Med 1982 (73):641–647

    Article  PubMed  CAS  Google Scholar 

  88. Lampkin BC, Higgins GR, Hammond D: Absence of neurotoxicity following massive intrathecal administration of methotrexate. Cancer 1967 (20):1780–1781

    Article  PubMed  CAS  Google Scholar 

  89. Bates SE, Raphaelson Ml, Price RA, McKeever P, Cohen S, Poplack DG: Ascending myelopathy after chemotherapy for central nervous system acute lymphoblastic leukemia: Correlation with cerebrospinal fluid myelin basic protein. Med Ped Oncol 1985 (13):4–8

    Article  CAS  Google Scholar 

  90. Ochs JJ, Berger P, Brecher ML, Sinks LF, Kinkel W, Freeman Al: Computed tomography brain scans in children with acute lymphocytic leukemia receiving methotrexate alone as central nervous system prophylaxis. Cancer 1980 (45):2274–22

    Article  PubMed  CAS  Google Scholar 

  91. Shapiro WR, Chernik NL, Posner JB: Necrotizing encephalopathy following intraventricular instillation of methotrexate. Arch Neurol 1973 (28):96–102

    PubMed  CAS  Google Scholar 

  92. Yanovski JA, Packer RJ, Levine JD, Davidson TL, Micalizzi M, D’Angio G: An animal model to detect the neuropsychological toxicity of anticancer agents. Med Ped Oncol 1989 (17):216–221

    Article  CAS  Google Scholar 

  93. Griffin TW, Rasey JS, Bleyer WA: The effect of photon irradiation on blood-brain permeability to methotrexate in mice. Cancer 1977 (40):1109–1113

    Article  PubMed  CAS  Google Scholar 

  94. Kamen BA, Moulder JE, Kun LE, Ring LE, Adams SM, Fish BL, Holcenberg JS: Effects of single dose and fractionated cranial irradiation on rat brain accumulation of methotrexate. Cancer Res 1984 (44):5092–5094

    PubMed  CAS  Google Scholar 

  95. Veninga TS, Dankert J, Ebels EJ, Fidler VJ: Early transient accumulation of methotrexate in the cerebrospinal fluid. Act Radiol Oncol 1984 (23):69–73

    Article  CAS  Google Scholar 

  96. Taylor EM, Geyer JR, Milstein JM, Shaw CM, Gerac JP, Wotton P, Hubbard BA, Bleyer AW: Rodent model of chemoradiotherapy-induced white matter necrosis. NCI Monograph 1988 (6):59–64

    Google Scholar 

  97. van der Kogel AJ, Sissingh HA: Effects of intrathecal methotrexate and cytosine arabinoside on the radiation tolerance of the rat spinal cord. Radiother and Oncol 1985 (4):239–254

    Article  Google Scholar 

  98. Suzuki K, Takemura T, Okeda R, Hatakeyama S: Vascular changes of methotrexate-related disseminated necrotizing leukoencephalopathy. Acta Neuropathol 1984 (65):145–149

    Article  PubMed  CAS  Google Scholar 

  99. Lampert PW, Tom Ml, Rider WD: Disseminated demyelination of the brain following Co 60 (gamma) radiation. Arch Pathol 1959 (68):322–330

    PubMed  CAS  Google Scholar 

  100. Gilbert MR, Harding BL, Grossman SA: Methotrexate neurotoxicity: in vitro studies using cerebellar explants from rats. Cancer Res 1989 (49):2502–2505

    PubMed  CAS  Google Scholar 

  101. Grossman SA, Reinhard CS: The intracerebral penetration of intraventricularly administered chemotherapeutic agents: a quantitative autoradiographic study. Proc Amer Assoc Cancer Res 1985 (26):923

    Google Scholar 

  102. Burch PA, Grossman SA, Reinhard CS: Spinal cord penetration of intrathecally administered cytarabine and methotrexate a quantitative audiographic study. J Natl Cancer Inst 1988 (80):1211–1216

    Article  PubMed  CAS  Google Scholar 

  103. Royds JA, Lilleyman JS, Timperley WR, Taylor CB: Cerebrospinal fluid enolase isoenzymes and neurotoxicity in early treatment of lymphoblastic leukemia. Archives of Dis Child 1984 (59):266–269

    Article  CAS  Google Scholar 

  104. Abelson HT: Methotrexate and central nervous system toxicity. Cancer Treat Rep 1978 (62):1999–2001

    PubMed  CAS  Google Scholar 

  105. Winick NJ, Kamen BA, Balis FM, Holcenberg J, Lester CM, Poplack DG: Folate and methotrexate polyglutamate tissue levels in rhesus monkeys following chronic low-dose methotrexate. Cancer Drug Delivery 1987 (4):25–31

    Article  PubMed  CAS  Google Scholar 

  106. Kamen BA: Methotrexate, folate and the brain. Neurotoxicol 1986 (7):209–216

    CAS  Google Scholar 

  107. Duch DS, Lee CL, Edelstein MD, Nichol CA: Biosynthesis of tetrahydrobiopterin in the presence of dihydrofolate reductase inhibitors. Molec Pharmacol 1983 (24):103–108

    CAS  Google Scholar 

  108. Johnston MV, Silverstein FS, Greenberg M, Knutsen CA, Chandler W, Phillips T, Ensminger WD: Effects of intraventricular methotrexate on cerebrospinal fluid monoamine metabolites in rhesus monkeys. Cancer Treat Rep 1986 (70):1205–1209

    PubMed  CAS  Google Scholar 

  109. Silverstein FS, Hutchinson RJ, Johnston MV: Cerebrospinal fluid biogenic amine metabolites in children during treatment for acute lymphocytic leukemia. Pediatr Res 1986 (20):285–291

    Article  PubMed  CAS  Google Scholar 

  110. Phillips PC, Thaler HT, Allen JC, Rotenberg DA: High dose leucovorin reverses acute high-dose methotrexate neurotoxicity in the rat. Ann Neurol 1989 (25):365–372

    Article  PubMed  CAS  Google Scholar 

  111. Kaminskas E, Nussey AC: Effects of methotrexate and of environmental factors on glycolysis and metabolic energy state in cultured Ehrlich ascites carcinoma cells. Cancer Res 1978 (38):2989–2996

    PubMed  CAS  Google Scholar 

  112. Metha BM, Glass JP, Shapiro WR: Serum and cerebrospinal fluid distribution of 5 methyltetrahydrofolate after intravenous calcium leucovorin and intra ommaya methotrexate administation in patients with meningeal carcinomatosis. Cancer Res 1983 (43):435–538

    Google Scholar 

  113. Kufe DW, Spriggs DR: Biochemical and cellular pharmacology of cytosine arabinoside. Semin Oncol 1985 (12):34–38

    PubMed  CAS  Google Scholar 

  114. Ho DHW: Distribution of kinase and deaminase of 1 D-arabinofuranosylcytosine in tissues of man and mouse. Cancer Res 1973 (33):2816–2820

    PubMed  CAS  Google Scholar 

  115. Gottlieb D, Bradstock K, Kout J, Robertson T, Lee C, Castaldi P: The neurotoxicity of high dose arabinoside is age related. Cancer 1987 (60):1439–1441

    Article  PubMed  CAS  Google Scholar 

  116. Hwang TL, Yung A, Esthey EM, Fields WS: Central nervous system toxicity with high dose Ara C. Neurology 1985 (35):1475–1479

    PubMed  CAS  Google Scholar 

  117. Benger A, Browman GP, Wacke IR: Clinical evidence of a cumulative effect of high dose cytarabine on the cerebellum in patients with acute leukemia. Cancer Treat Rep 1981 (61):240–241

    Google Scholar 

  118. Damon LE, Mass R, Linker CA: The association between high-dose cytarabine neurotoxicity and renal insufficiency. J Clin Oncol 1989 (7):1563–1568

    PubMed  CAS  Google Scholar 

  119. Salinsky MC, Levine R, Aubuchon JP, Schutta HS: Acute cerebellar dysfunction with high dose Ara C therapy. Cancer 1983 (51):426–429

    Article  PubMed  CAS  Google Scholar 

  120. Winkelman MD, Hines JD: Cerebellar degeneration caused by the high-dose cytosine arabinoside: a clinicopathological study. Ann Neurol 1983 (14):520–527

    Article  PubMed  CAS  Google Scholar 

  121. Spector R: Pharmacokinetics and metabolism of cytosine arabinoside in the central nervous system. J Pharm Exp Ther 1982 (22):1–6

    Google Scholar 

  122. Lopez JA, Agarival RP: Acute cerebellar toxicity after high dose cytarabine associated with CNS accumulation of its metabolite uracil arabinoside. Cancer Treat Rep 1984 (68):1309–1310

    PubMed  CAS  Google Scholar 

  123. Zimm S, Collins JM, Miser J, Chatteir JD, Poplack DG: Cytosine arabinoside cerebrospinal fluid kinetics. Clin Pharm Ther 1984 (35):826–830

    Article  CAS  Google Scholar 

  124. Lopez JA, Nassif E, Vannicola P, Krikorian JG, Agarwal RP: Central nervous sytem pharmacokinetics of high dose cytosine arabinoside. J Neur Oncol 1985 (3):119–124

    Article  CAS  Google Scholar 

  125. Band PR, Golland JF, Bernard J: Treatment of central nervous system leukemia with intrathecal cytosine arabinoside. Cancer 1973 (32):744–748

    Article  PubMed  CAS  Google Scholar 

  126. Breuer AC, Pitman SW, Dawson DM: Paraparesis following intrathecal cytosine arabinoside. Cancer 1977 (40):2817–2822

    Article  PubMed  CAS  Google Scholar 

  127. Hwang TL, Yung WKA, Lee Y, Borit A, Fields WS: High-dose Ara-C related leucoencephalopathy. J Neuro Oncol 1986 (3):335–339

    Article  CAS  Google Scholar 

  128. Seil FJ, Leiman AC, Woodward WR: Cytosine arabinoside effects on cerebellum in tissue culture. Brain Res 1980 (186):393–408

    Article  PubMed  CAS  Google Scholar 

  129. Yamamo T, Shimada M, Abe Y, Otha S, Ohno M: Destruction of external granular layer and subsequent cerebellar abnormalities. Acta Neuropathol 1983 (59):41–47

    Article  Google Scholar 

  130. Adlard BFP, Dobbing J, Sands J: A comparison of the effects of cytosine arabinoside and adenine arabinoside on some aspects of brain growth and development in the rat. Br J Pharmacol 1975 (54):33–39

    PubMed  CAS  Google Scholar 

  131. Aguayo AL, Rome JS, Bray GM: Experimental necrosis of and arrest of proliferationof Schwann cells by cytosine arabinoside. J Neurocytol 1975 (4):663–674

    Article  PubMed  CAS  Google Scholar 

  132. Koenig H: Production of injury to feline central nervous system with nucleic acid antimetabolites. Science 1958 (127):1238–1239

    Article  PubMed  CAS  Google Scholar 

  133. Nand S, Messmore HL Jr, Patel R, Fischer SG, Fischer Rl: Neurotoxicity associated with high dose cytosine arabinoside. J Clin Oncol 1986 (4):571–575

    PubMed  CAS  Google Scholar 

  134. Myers CE: The pharmacology of the fluoropyrimidines. Pharmacol Rev 1981 (33):1–15

    PubMed  CAS  Google Scholar 

  135. Moertel CG, Reitemeir RJ, Bolton CF, Shorter RG: Cerebellar ataxia associated with fluorinated pyrimidine therapy. Cancer Chemother Rep 1964 (41):15–18

    PubMed  CAS  Google Scholar 

  136. Lyngh HT, Droszcz CP, Albano WA, Lynch JF: Organic brain syndrome secondary to 5-fluorouracil toxicity. Dis Colon Rectum 1981 (24):130–131

    Article  Google Scholar 

  137. Bourk E, West CR, Chheda G, Tower DB: Kinetics of entry and distribution of 5-fluorouracil in cerebrospinal fluid and brain following intravenous injection in a primate. Cancer Res 1973 (33):1735–1745

    Google Scholar 

  138. Koenig H, Patel A: Biochemical basis of the acute cerebellar syndrome in 5-fluorouracil chemotherapy. Trans Am Neurol Assoc 1969 (94):290–292

    PubMed  CAS  Google Scholar 

  139. Diasia RB, Beavers TL, Carpenter JT: Familial deficiency of dihydropyrimidine dehydrogenase. J Clin Invest 1988 (81):47–51

    Article  Google Scholar 

  140. Kuzuhara S, Ohkoshi N, Kanemarv K: Subacute leukoencephalopathy induced by carmofur, a 5-flourouracil derivative. J Neurol 1987 (234):365–370

    Article  PubMed  CAS  Google Scholar 

  141. Okeda R, Shibutani M, Matsuo T, Kuroiwa T: Subacute neurotoxicity of 5-fluorouracil and its derivative carmofur in cats. Acta Pathol Ipn 1988 (38):1255–1266

    CAS  Google Scholar 

  142. Okeda R, Karakama T, Kimura S: Neuropathologic study on chronic neurotoxicity of 5-fluorouracil and its masked compound in dog. Acta Neuropathol 1984(63):334–343

    Article  PubMed  CAS  Google Scholar 

  143. Yamamoto J, Yamashito K, Ken Ch: Effect of coadministration of uracil on the toxicity of tegafur. J Pharm Sciences 1984 (73):212–214

    Article  CAS  Google Scholar 

  144. Kerr G, Zimm S, Collins JM, O’Neil D, Poplack DG: Effect of intravenous dose and schedule on cerebrospinal fluid. Pharmacokinetics of 5-fluorouracil in the monkey. Cancer Res 1984 (44):4929–4932

    PubMed  CAS  Google Scholar 

  145. Colvin M: The alkylating agents. In: Chabner B (ed) Pharmacologic Principles of Cancer Treatment. Saunders, Philadelphia 1982 pp 276–308

    Google Scholar 

  146. Pillans PI, Ponzi SF, Parker Ml: Cyclophosphamide induced DNA strand breaks in mouse embryo cephalic tissue in vivo. Carcinogenesis 1989 (10):83–85

    Article  PubMed  CAS  Google Scholar 

  147. Colvin M: The comparative pharmacology of cyclophosphamide and ifosfamide. Semin Oncol 1982 (9):2–7

    PubMed  CAS  Google Scholar 

  148. Meanwell CA, Blake AE, Kelly KA, Honigsberger L, Blackledge G: Prediction of ifosfamide/mesma associated encephalopathy. Eur J Cancer Clin Oncol 1986 (22):815–819

    Article  PubMed  CAS  Google Scholar 

  149. Goren MR, Wright RK, Pratt CB, Horowitz ME, Dodge RK, Viar JM, Kovnar EH: Potentiation of ifosfamide neurotoxicity hematotoxicity and tubular nephrotoxicity by prior cisdiamminedichloroplatinum therapy. Cancer Res 1987 (47):1457–1460

    PubMed  CAS  Google Scholar 

  150. Pratt CB, Green AA, Horowitz ME, Meyer WH, Etcubanas E, Douglas E, Kovnar E: Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna. J Clin Oncol 1986 (4):1253–1261

    PubMed  CAS  Google Scholar 

  151. Lind MJ, Margison JM, Cerny T, Thatcher N, Wilkinson PM: Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res 1989 (49):753–757

    PubMed  CAS  Google Scholar 

  152. Goren MP, Wright RK, Pratt CB, Pell FE: Dechlorethylation of ifosfamide and neurotoxicity. Lancet 1986 (2):1219–1220

    Article  PubMed  CAS  Google Scholar 

  153. Osborne RJ, Slevin ML: Iphosphamide, mesna and encephalopathy. Lancet 1986 (1):601

    Google Scholar 

  154. Heim ME, Fiene R, Schick E, Wolpert E, Queiber W: Central nervous system side effects following ifosphamide monotherapy of advanced renal carcinoma. J Cancer Res Clin Oncol 1981 (100):113–116

    Article  PubMed  CAS  Google Scholar 

  155. Arndt CAS, Balis FM, Mc Cully CL, Colvin M, Poplack DG: Cerebrospinal fluid penetration of active metabolites of cyclophosphamide and ifosfamide in rhesus monkeys. Cancer Res 1988 (48):2113–2115

    PubMed  CAS  Google Scholar 

  156. Cerny T, Castiglione M, Brunner K, Kupfer A, Martineli G, Lind G: Ifosfamide by continuous infusion to prevent encephalopathy. Lancet 1990 (335):175

    Article  PubMed  CAS  Google Scholar 

  157. Burger PC, Kamenar E, Schold SC, Fay JW, Phillops GL, Herzig GP: Encephalomyelopathy following high-dose BCNU therapy. Cancer 1981 (48):1318–1327

    Article  Google Scholar 

  158. Schold SC, Fay JW: Central nervous system toxicity from high-dose treatment of systemic cancer. Neurology 1980 (30):429

    Google Scholar 

  159. Kleinschmidt-De Masters BK, Geier JM: Pathology of high-dose intraarterial BCNU. Surg Neurol 1989 (31):435–443

    Article  Google Scholar 

  160. Mahaley MS, Whaley RA, Blue M, Bertsh L: Central neurotoxicity following intracarotid BCNU chemotherapy for malignant gliomas. J Neuro Oncol 1986 (3):297–314

    Article  Google Scholar 

  161. Dewys WD, Fowler EH: Report of vasculitis and blindness after intracarotid injection of 1,3-bis (2 chloroethyl)-1 -nitrosurea (BCNU;NSC-409962) in dogs. Cancer Chemother Rep 1973 (57):33–40

    PubMed  CAS  Google Scholar 

  162. Omojola MF, Fox AJ, Auer RN, Vinnuela FV: Hemorrhagic encephalitis produced by selective non-occlusive intracarotid BCNU injection in dogs. J Neurosurg 1982 (57)791–796

    Article  PubMed  CAS  Google Scholar 

  163. Crafts DC, Levin VA, Nielson S: Intracarotid BCNU (NSC-409962): A toxicity study in six rhesus monkeys. Cancer Treat Rep 1976 (2):541–545

    Google Scholar 

  164. Goldlewski A, Szczech J: The morphology and histochemistry of adult rat neurocytes after BCNU administration. Fol Histochem Cytobiol 1985 (23):221–230

    Google Scholar 

  165. Godlewski A: Morphological alterations in blood vessel endothelia of rat brain after administration of CCNU. Neoplasma 1986 (33):437–445

    PubMed  CAS  Google Scholar 

  166. Frytak S, Shaw JN, O’Neil BP, Lee RE, Eagan RT, Shaw EG, Richardson RL, Coles DT, Jett JR: Leukoencephalopathy in small cell lung cancer patients receiving prophylactic cranial irradiation. Am J Clin Oncol 1989 (12)27–33

    Article  PubMed  CAS  Google Scholar 

  167. Gutin Ph, Weiss HD, Wiernik Ph, Wlaker MD: Intrathecal N, N’, Ntriethylenethiophosphoramide (thiotepa) in the treatment of malignant disease. Cancer 1976 (38):1471–1475

    Article  PubMed  CAS  Google Scholar 

  168. Garcia JH, Sandbank U, Gutin P: Multifocal leukoencephalopathy in adult leukemia: histologic features and etiologic considerations. Acta Neuropath 1977 (40):273–276

    Article  PubMed  CAS  Google Scholar 

  169. Strong JM, Collins JM, Lester C, Poplack DG: Pharmacokinetics of intraventricular and intravenous N, N’,Ntriethylenethiophosphoramide (thiotepa) in rhesus monkeys and humans. Cancer Res 1986 (46):6101–6104

    PubMed  CAS  Google Scholar 

  170. Young RL, Ozols RF, Myers CE: The antracycline antineoplastic drugs. N Engl J Med 1981 (305):139–153

    Article  PubMed  CAS  Google Scholar 

  171. Goormaghtight E, Ruysschaert JM: Antracycline glycoside-membrane interactions. Biochim Biophys Acta 1984 (779):271–288

    Google Scholar 

  172. Merker PC, Lewis MR, Walker MD, Richardson EP Jr: Neurotoxicity of adriamycin (doxorubicin) perfusion through the cerebrospinal fluid spaces of the rhesus monkey. Toxico Appl Pharmacol 1978 (44):191–205

    Article  CAS  Google Scholar 

  173. Siegal T, Melamed E, Sandbank V, Catane R: Early and delayed neurotoxicity of motoxantrone and doxorubicin following subarachnoid injection. J Neuro Oncol 1988 (6):135–140

    Article  CAS  Google Scholar 

  174. Neuwelt EA, Pagel M, Barnett P, Glassbert M, Frenkel EP: Pharmacology and toxicity of intracarotid adriamycin administration following ostmotic blood brain barrier modification. Cancer Res 1981 (41):4466–4470

    PubMed  CAS  Google Scholar 

  175. Cho ES, Spencer PS, Jortner BS, Schaumburg HH: A single intravenous injection of doxorubicin induces sensory neuropathy in rats. Neurotoxicol 1980 (1):583–591

    CAS  Google Scholar 

  176. Cavanagh JB, Tomiwa K, Munro PMG: Nuclear and nucleolar damage in adriamycin-induced toxicity to rat sensory ganglion cells. Neuropath Appl Neurobiol 1987 (13):23–28

    Article  CAS  Google Scholar 

  177. Bigotte L, Olsson Y: Distribution and toxic effects of intravenously injected epirubicin on the central nervous system of the mouse. Brain 1989 (112):457–469

    Article  PubMed  Google Scholar 

  178. Hall C, Dougherty WJ, Lebish U, Brock PG, Man A: Warning against use of intrathecal mitoxantrone. Lancet 1989(1)734

    Article  PubMed  CAS  Google Scholar 

  179. Kondo A, Òhnish A, Nagara H, Tateishi J: Neurotoxicity in primary sensory neurons of adriamycin administered through retrograde axoplasmic transport in rats. Neuropathol Appl Neurobiol1987(13):177–192

    Article  PubMed  CAS  Google Scholar 

  180. England JD, Asbury AK, Rhee EK, Summer AJ: Lethal retrograde axoplasmic transport of doxorubicin to motor neurons. Brain 1988 (111):915–926

    Article  PubMed  Google Scholar 

  181. England JD, Rhee EK, Said G, Summer AJ: Schwann cell degeneration induced by doxorubicin. Brain 1988 (111):901–913

    Article  PubMed  Google Scholar 

  182. Deliconstantinos G, Kopeikina T, Siboukidou L, Villiotou V: Evaluation of membrane fluidity effects and enzyme activities alterations in adriamycin neurotoxicity. Biochemic Pharmacol 1987 (36):1153–1161

    Article  CAS  Google Scholar 

  183. Kahman BD: Cyclosporine. N Engl J Med 1989 (321):1725–1738

    Article  Google Scholar 

  184. Atkinson K, Boland J, Britton K, Biggs J: Blood and tissue distribution of cyclosporine in humans and in mice. Transplant Proc 1983 (1):214–217

    Google Scholar 

  185. de Groen PC, Aksamit AJ, Rakela J, Forbes GS, From RAF: Central nervous system toxicity after liver transplantation: the role of cyclosporine and cholesterol. N Engl J Med 1987 (317):861–866

    Article  PubMed  Google Scholar 

  186. Tollemar J, Ringeden O, Ericzon BG, Tyden G: Cyclosporine associated central nervous system toxicity. N Engl J Med 1988 (318):788–789

    Article  Google Scholar 

  187. Brown Z, Neild GH: Cyclosporine inhibits prostacyclin production by cultured human endothelial cells. Transplant Proc 1987 (19):1178–1180

    PubMed  CAS  Google Scholar 

  188. Thompson CB, June CH, Sullivan KM, Thomas ED: Association between cyclosporine neurotoxicity and hypomagnesaemia. Lancet 1984 (11):116–120

    Google Scholar 

  189. Bhat BD, Meriano FV, Buchwald D: Cyclosporineassociated central nervous system toxicity. N Engl J Med 1988 (318):788

    Article  Google Scholar 

  190. Durrant S, Chipping PM, Palmer S, Gordon-Smith EC: Cyclosporin A, methylprednisolone and convulsions. Lancet 1982 (11):829–830

    Article  Google Scholar 

  191. Davenport A, Will EJ, Davison AM, Ironside JW: Toxicity of cyclosporin metabolites. Lancet 1988 (1):333

    Article  Google Scholar 

  192. Kunzendorf U, Brockmoller J, Jochmisen F, Keller F, Walz G, Offerman G: Cyclosporine metabolites and central nervous system toxicity. Lancet 1988 (2):1223

    Article  Google Scholar 

  193. Adams F, Quesada JR, Gutterman JV: Neuropsychiatry manifestations of human leukocyte interferon therapy in patients with cancer. JAMA 1984 (252):938–941

    Article  PubMed  CAS  Google Scholar 

  194. Johnson DH, Hande KH, Hainsworth JD, Greco FA: Neurotoxicity of interferon. Cancer Treat Rep 1983 (67):958–961

    Google Scholar 

  195. Rohatiner AZS, Prior PF, Burton AC, Smith AT, Balkwill FR, Lister TA: Central nervous system toxicity of interferon. Br J Cancer 1983 (47):422–427

    Article  Google Scholar 

  196. Rosenberg SA, Lotze MT, Muul LM: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 1987 (316):889–897

    Article  PubMed  CAS  Google Scholar 

  197. Habit DV, Lipton R, Cantell K: Interferon crosses blood-brain barrier in monkey. Proc Soc Exp Biol Med 1975 (49):287–293

    Google Scholar 

  198. Salazar AM, Gibb S, Gajdusek DC, Smith RA: Clinical use of interferon: central nervous system disorders. In: Came PE, Carter NA (eds) Interferon and their applications. Berlin Heidelberg Tokyo 1984 (71) pp 471–496

    Google Scholar 

  199. Jacobs L, O’Malley, Freemand A, Murawski J, Ekes R: Intrathecal interferon in multiple sclerosis. Arch Neurol 1982 (39):609–615

    PubMed  CAS  Google Scholar 

  200. Obbens E, Feun LG, Leavens ME, Savaraj N, Stewart D, Gutterman JV: Phase I clinical trial of intralesional or intraventricular leucocyte interferon for intracranial malignancies. J Neuro Oncol 1985 (3):61–67

    Article  CAS  Google Scholar 

  201. Calvet MC, Gresser I: Interferon enhances the excitability of cultured neurones. Nature 1979 (278):558–560

    Article  PubMed  CAS  Google Scholar 

  202. Merrill JE: Effects of lymphokines and monokines on glial cells in vitro and in vivo. In: Goetzl EJ, Spector NH (eds) Physiology and Diseases. AR Liss, New York 1989 pp 89–97

    Google Scholar 

  203. Kirchner M: Interferons, a group of multiple lymphokines. Springer Semin Immunopathol 1984 (7):347–374

    Article  PubMed  CAS  Google Scholar 

  204. Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CA, Custer MC, Rosenberg SA: In vivo administration of purified interleukin-2. J Immunol 1985 (135):2865–2875

    PubMed  CAS  Google Scholar 

  205. Byrne Gl, Lehmann L, Kirschbaum JG, Borden EC, Lee CM, Brown RR: Induction of tryptophan degradation in vitro and in vivo: a interferonstimulated activity. J Interf Res 1986 (6):389–396

    Article  CAS  Google Scholar 

  206. Brown RR, Lee CM, Kohler PC, Hank JA, Storer BE, Sondel PM: Altered tryptophan and neopterin metabolism in cancer patients treated with recombinant interleukin-2. Cancer Res 1989 (49):4941–4944

    PubMed  CAS  Google Scholar 

  207. Elison MD, Povlishock JT, Merchant RE: Blood brain barrier dysfunction in cats following recombinant interleukin-2 infusion. Cancer Res 1987(47):5765–5770

    Google Scholar 

  208. Lee KY, Talpaz M, Rothberg JM, Murray JL, Papadopoulos N, Plager C, Benjamin R, Levitt D, Gutterman J: Concomitant administration of recombinant human interleukin-2 and recombinant interferon-2A in cancer patients: a phase I study. J Clin Oncol 1989 (7):1726–1732

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Pharmacology and Chemotherapy Unit, Université Libre de Bruxelles School of Medicine, Hôpital Erasme, Route de Lennik 808, 1070, Brussels, Belgium

    Diamon Gangji

  2. Department of Neurology, Université Libre de Bruxelles School of Medicine, Hôpital Erasme, Route de Lennik 808, 1070, Brussels, Belgium

    Jerzy Hildebrand

  3. Clinical Research Department, Duphar BV, C.J. van Houtenlaan 36, 1381 CP, Weesp, The Netherlands

    Roland Gerritsen van der Hoop

Authors
  1. Diamon Gangji
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jerzy Hildebrand
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roland Gerritsen van der Hoop
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Service de Neurologie, Hôpital Erasme Université Libre de Bruxelles, Route de Lennik, 808, 1070, Bruxelles, Belgium

    Jerzy Hildebrand

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Gangji, D., Hildebrand, J., van der Hoop, R.G. (1990). Mechanisms of Neurotoxicity and Experimental Models. In: Hildebrand, J. (eds) Neurological Adverse Reactions to Anticancer Drugs. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76142-3_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-76142-3_3

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-76144-7

  • Online ISBN: 978-3-642-76142-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation